Oncology
-
To show additional prognostic information about the mutational profile and new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification of adenocarcinoma (ADC) in patients without epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatments. ⋯ These results indicate that the mutational profile and new IASLC/ATS/ERS classification provide additional prognostic information about lung ADC.